Literature DB >> 17600108

Concise review: prospects of stem cell therapy for temporal lobe epilepsy.

Ashok K Shetty1, Bharathi Hattiangady.   

Abstract

Certain regions of the adult brain have the ability for partial self-repair after injury through production of new neurons via activation of neural stem/progenitor cells (NSCs). Nonetheless, there is no evidence yet for pervasive spontaneous replacement of dead neurons by newly formed neurons leading to functional recovery in the injured brain. Consequently, there is enormous interest for stimulating endogenous NSCs in the brain to produce new neurons or for grafting of NSCs isolated and expanded from different brain regions or embryonic stem cells into the injured brain. Temporal lobe epilepsy (TLE), characterized by hyperexcitability in the hippocampus and spontaneous seizures, is a possible clinical target for stem cell-based therapies. This is because these approaches have the potential to curb epileptogenesis and prevent chronic epilepsy development and learning and memory dysfunction after hippocampal damage related to status epilepticus or head injury. Grafting of NSCs may also be useful for restraining seizures during chronic epilepsy. The aim of this review is to evaluate current knowledge and outlook pertaining to stem cell-based therapies for TLE. The first section discusses the behavior of endogenous hippocampal NSCs in human TLE and animal models of TLE and evaluates the role of hippocampal neurogenesis in the pathophysiology and treatment of TLE. The second segment considers the prospects for preventing or suppressing seizures in TLE using exogenously applied stem cells. The final part analyzes problems that remain to be resolved before initiating clinical application of stem cell-based therapies for TLE. Disclosure of potential conflicts of interest is found at the end of this article.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17600108      PMCID: PMC3612506          DOI: 10.1634/stemcells.2007-0313

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  149 in total

1.  Clonal and population analyses demonstrate that an EGF-responsive mammalian embryonic CNS precursor is a stem cell.

Authors:  B A Reynolds; S Weiss
Journal:  Dev Biol       Date:  1996-04-10       Impact factor: 3.582

Review 2.  Hippocampal resections and the use of human tissue in defining temporal lobe epilepsy syndromes.

Authors:  D D Spencer; S S Spencer
Journal:  Hippocampus       Date:  1994-06       Impact factor: 3.899

3.  Childhood generalized and mesial temporal epilepsies demonstrate different amounts and patterns of hippocampal neuron loss and mossy fibre synaptic reorganization.

Authors:  G W Mathern; T L Babb; P S Mischel; H V Vinters; J K Pretorius; J P Leite; W J Peacock
Journal:  Brain       Date:  1996-06       Impact factor: 13.501

4.  The pathogenic and progressive features of chronic human hippocampal epilepsy.

Authors:  G W Mathern; T L Babb; J P Leite; K Pretorius; K M Yeoman; P A Kuhlman
Journal:  Epilepsy Res       Date:  1996-12       Impact factor: 3.045

5.  Intracerebroventricular kainic acid administration in adult rat alters hippocampal calbindin and non-phosphorylated neurofilament expression.

Authors:  A K Shetty; D A Turner
Journal:  J Comp Neurol       Date:  1995-12-25       Impact factor: 3.215

6.  Prolonged increases in neurotrophic activity associated with kainate-induced hippocampal synaptic reorganization.

Authors:  D H Lowenstein; M S Seren; F M Longo
Journal:  Neuroscience       Date:  1993-10       Impact factor: 3.590

7.  Withdrawal of differentiation inhibitory activity/leukemia inhibitory factor up-regulates D-type cyclins and cyclin-dependent kinase inhibitors in mouse embryonic stem cells.

Authors:  P Savatier; H Lapillonne; L A van Grunsven; B B Rudkin; J Samarut
Journal:  Oncogene       Date:  1996-01-18       Impact factor: 9.867

8.  Influence of the type of initial precipitating injury and at what age it occurs on course and outcome in patients with temporal lobe seizures.

Authors:  G W Mathern; J K Pretorius; T L Babb
Journal:  J Neurosurg       Date:  1995-02       Impact factor: 5.115

9.  The pathophysiologic relationships between lesion pathology, intracranial ictal EEG onsets, and hippocampal neuron losses in temporal lobe epilepsy.

Authors:  G W Mathern; T L Babb; J K Pretorius; M Melendez; M F Lévesque
Journal:  Epilepsy Res       Date:  1995-06       Impact factor: 3.045

10.  Neurogenesis in the dentate gyrus of the adult rat: age-related decrease of neuronal progenitor proliferation.

Authors:  H G Kuhn; H Dickinson-Anson; F H Gage
Journal:  J Neurosci       Date:  1996-03-15       Impact factor: 6.167

View more
  51 in total

1.  After the storm: from windswept to spiny trees.

Authors:  Detlev Boison
Journal:  Epilepsy Curr       Date:  2011-09       Impact factor: 7.500

Review 2.  Stem cells as a potential therapy for epilepsy.

Authors:  Steven N Roper; Dennis A Steindler
Journal:  Exp Neurol       Date:  2012-01-13       Impact factor: 5.330

3.  Medial ganglionic eminence-derived neural stem cell grafts ease spontaneous seizures and restore GDNF expression in a rat model of chronic temporal lobe epilepsy.

Authors:  Ben Waldau; Bharathi Hattiangady; Ramkumar Kuruba; Ashok K Shetty
Journal:  Stem Cells       Date:  2010-07       Impact factor: 6.277

4.  Tracking stem cell differentiation in the setting of automated optogenetic stimulation.

Authors:  Albrecht Stroh; Hsing-Chen Tsai; Li-Ping Wang; Feng Zhang; Jenny Kressel; Alexander Aravanis; Nandhini Santhanam; Karl Deisseroth; Arthur Konnerth; M Bret Schneider
Journal:  Stem Cells       Date:  2011-01       Impact factor: 6.277

Review 5.  Adenosine augmentation therapies (AATs) for epilepsy: prospect of cell and gene therapies.

Authors:  Detlev Boison
Journal:  Epilepsy Res       Date:  2009-05-09       Impact factor: 3.045

6.  Human mesenchymal stem cell grafts engineered to release adenosine reduce chronic seizures in a mouse model of CA3-selective epileptogenesis.

Authors:  Tianfu Li; Gaoying Ren; David L Kaplan; Detlev Boison
Journal:  Epilepsy Res       Date:  2009-02-12       Impact factor: 3.045

7.  Geniposide attenuates epilepsy symptoms in a mouse model through the PI3K/Akt/GSK-3β signaling pathway.

Authors:  Hongtao Wei; Guanghui Duan; Jianxun He; Qinglong Meng; Yuxian Liu; Wanqiang Chen; Yongpeng Meng
Journal:  Exp Ther Med       Date:  2017-11-14       Impact factor: 2.447

Review 8.  Hippocampal injury-induced cognitive and mood dysfunction, altered neurogenesis, and epilepsy: can early neural stem cell grafting intervention provide protection?

Authors:  Ashok K Shetty
Journal:  Epilepsy Behav       Date:  2014-01-13       Impact factor: 2.937

Review 9.  Progress in neuroprotective strategies for preventing epilepsy.

Authors:  Munjal M Acharya; Bharathi Hattiangady; Ashok K Shetty
Journal:  Prog Neurobiol       Date:  2007-12-08       Impact factor: 11.685

Review 10.  Recent progress on tissue-resident adult stem cell biology and their therapeutic implications.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Stem Cell Rev       Date:  2008       Impact factor: 5.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.